Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

• the present invention relates to certain novel compounds.
• the present invention relates to compounds that activate both the alpha and gamma subtypes of the human peroxisome proliferator activated receptor.
• the present invention also relates to methods for preparing the compounds and methods for prevention or treatment of PPAR mediated diseases or conditions.
• HMG CoA reductase inhibitors are useful for treating conditions characterized by high LDL-c levels. It has been shown that lowering LDL-c is not sufficient for reducing the risk of cardiovascular disease in some patients, particularly those with normal LDL-c levels. This population pool is identified by the independent risk factor of low HDL-c.
• the increased risk of cardiovascular disease associated with low HDL-c levels has not yet been successfully addressed by drug therapy (i.e., currently there are no drugs on the market that are useful for raising HDL-c >40%). (Bisgaier, C. L; Pape, M. E. Curr. Pharm. Des. 1998, 4, 53-70).
• Syndrome X (including metabolic syndrome) is loosely defined as a collection of abnormalities including hyperinsuinlemia, obesity, elevated levels of trigycerides, uric acid, fibrinogen, small dense LDL-c particles, and plasminogen activator inhibitor 1 (PAI-1 ), and decreased levels of HDL-c.
• abnormalities including hyperinsuinlemia, obesity, elevated levels of trigycerides, uric acid, fibrinogen, small dense LDL-c particles, and plasminogen activator inhibitor 1 (PAI-1 ), and decreased levels of HDL-c.
• NIDDM is described as insulin resistance which in turn causes anomalous glucose output and a decrease in glucose uptake by skeletal muscle. These factors eventually lead to impaired glucose tolerance (IGT) and hyperinsulinemia.
• ITT impaired glucose tolerance
• Peroxisome Proliferator Activated Receptors are orphan receptors belonging to the steroid/retinoid receptor superfamily of ligand-activated transcription factors. See, for example, Willson, T. M. and Wahli, W., Curr. Opin. Chem. Biol., (1997), Vol. 1, pp 235-241.
• Three mammalian Peroxisome Proliferator-Activated Receptors have been isolated and termed PPAR-alpha, PPAR-gamma, and PPAR-delta (also known as NUC1 or PPAR-beta). These PPARs regulate expression of target genes by binding to DNA sequence elements, termed PPAR response elements (PPRE).
• Certain compounds that activate or otherwise interact with one or more of the PPARs have been implicated in the regulation of triglyceride and cholesterol levels in animal models. See, for example, WO 01/40207, WO 01/00603, WO 97/31907, WO 02/46174 (Glaxo Group Ltd et al).
• R 3 and R 4 are independently H, d. 6 alkyl, -OC 1-6 alkyl, halogen, OH, C 2-6 alkenyl or CF 3 ;
• R 5 is H, C 1-6 alkyl (optionally substituted by one or more halogens, -COphenyl, OC ⁇ -6 alkyl, phenyl, morpholino) or C 2-6 alkenyl;
• R 6 is C 1-6 alkyl, halogen, -OCH 2 phenyl, phenyl (optionally substituted by C 1-3 alkyl), morpholino, pyrrolidino, piperidino, thiophenyl, furanyl, pyridinyl or -OC 2- 6 alkenyl.
• the present invention provides a pharmaceutical composition comprising a compound of the invention, preferably in association with a pharmaceutically acceptable diluent or carrier.
• the present invention provides a compound of the invention for use in therapy, and in particular, in human medicine.
• the present invention provides a compound of the invention for use in treating a human PPAR ("hPPAR”) mediated disease or condition.
• hPPAR human PPAR
• the present invention discloses a method for prevention or treatment of a hPPAR mediated disease or condition comprising administration of a compound of this invention.
• the present invention provides the use of a compound of the invention for the manufacture of a medicament for the treatment of a hPPAR mediated disease or condition.
• hPPARmediated diseases or conditions include dyslipidemia including associated diabetic dyslipidemia and mixed dyslipidemia, obesity, syndrome X (as defined in this application this embraces metabolic syndrome), heart failure, hypercholesteremia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, inflammation, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lining and gut and regulation of appetite and food intake in subjects suffering from disorders such as obesity, bulimia, and anorexia nervosa.
• the compounds of the invention are potentially useful in the treatment and prevention of cardiovascular diseases and conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and mixed dyslipidaemia.
• a compound of the invention means a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolyzable ester thereof. While hydrolyzable esters are included in the scope of this invention, the acids are preferred because the data suggests that while the esters are useful compounds, it may actually be the acids to which they hydrolyze that are the active compounds. Esters that hydrolyze readily can produce the carboxylic acid in the assay conditions or in vivo. Generally the carboxylic acid is active in both the binding and transient transfection assays, while the ester does not usually bind well but is active in the transient transfection assay presumably due to hydrolysis. Preferred hydrolysable esters are C 1-6 alkyl esters wherein the alkyl group may be straight chain or branched chain. Methyl or ethyl esters are more preferred.
• the compounds of the invention are modulators of PPAR alpha and PPAR gamma. In one aspect they are agonists or partial agonists of the relevant PPAR.
• the compound of formula (I) is suitably a selective dual agonist of PPAR alpha and gamma.
• agonist or “activating compound”, or “activator”, or the like, is meant those compounds which have a pKi of at least 6.0 preferably at least 7.0 to the relevant PPAR, for example hPPAR alpha in the binding assay described below, and which achieve at least 50% activation of the relevant PPAR relative to the appropriate indicated positive control in the transfection assay described below at concentrations of 10 "5 M or less.
• Partial agonists can be defined as compounds that transactivate the relevant PPAR, for example PPAR alpha in CV1 cells with less than 50% fold activation compared to the reference PPAR alpha full agonist in the transfection assays of the type described below.
• a "selective dual hPPAR alpha/gamma agonist” is a hPPARalpha/gamma agonist whose EC 50 for PPARalpha and PPAR gamma is at least 10 fold lower than its EC 50 for PPAR delta.
• EC 50 is defined in the transfection assay described below and is the concentration at which a compound achieves 50% of its maximum activity.
• R 1 and R 2 are independently C- ⁇ -3 alkyl. Preferably R 1 and R 2 are both C 1-3 alkyl, more preferably R 1 and R 2 are both methyl.
• R 4 is H.
• R 3 is C 1-3 alkyl or -OC- ⁇ -3 alkyl.
• R 3 is methyl or -OCH 3 .
• R 3 is preferably ortho to the depicted Oxygen.
• R 5 is methyl
• R 6 is C 1-6 alkyl, preferably tertiary butyl. Preferably R 6 is in the para position on the phenyl ring.
• the compound of formula (I) is a compound of formula (la)
• R 1 and R 2 are independently H or C 1-3 alkyl
• R 3 and R 4 are independently H, C ⁇ -6 alkyl, -OC 1-6 alkyl, halogen, OH, C 2-6 alkenyl, CF 3 ;
• R 5 is H, C ⁇ -6 alkyl or CF 3 ;
• R 6 is C 1-6 alkyl (optionally substituted by one or more halogens), halogen, -OC -6 alkyl.
• R 1 and R 2 in formula (la) are independently C 1-3 alkyl.
• R 1 and R 2 are both C 1-3 alkyl, more preferably R 1 and R 2 are both methyl.
• R 4 is H
• R 3 is C 1-3 alkyl or -OC 1-3 alkyl.
• R 3 is methyl or -OCH 3 .
• R 3 is preferably ortho to the depicted oxygen.
• R 5 is methyl.
• R 6 is C 1-6 alkyl, preferably tertiary butyl. Preferably R 6 is in the para position in the phenyl ring
• Suitable compounds of the invention include:
• the compounds of the present invention may also be utilized in the form of a pharmaceutically acceptable salt or solvate thereof.
• physiologically acceptable salts of the compounds of formula (I) include conventional salts formed from pharmaceutically acceptable inorganic or organic acids or bases as well as quaternary ammonium acid addition salts.
• suitable acid salts include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, palmoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulfonic, methanesulfonic, naphthalene-2-sulfonic, benzenesulfonic hydroxynaphthoic, hydroiodic, malic, steroic, tannic and the like.
• acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable salts.
• suitable basic salts include sodium, lithium, potassium, magnesium, aluminium, calcium, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine salts.
• References hereinafter to a compound according to the invention include both compounds of formula (I) and their pharmaceutically acceptable salts and solvates.
• compositions are conveniently administered in the form of pharmaceutical compositions.
• Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients. While it is possible that compounds of the present invention may be therapeutically administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical composition.
• the carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
• the present invention further provides for a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers therefore and, optionally, other therapeutic and/or prophylactic ingredients.
• compositions include those suitable for oral, parenteral (including subcutaneous e.g. by injection or by depot tablet, intradermal, intrathecal, intramuscular e.g. by depot and intravenous), rectal and topical (including dermal, buccal and sublingual) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
• the compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound ("active ingredient") with the carrier which constitutes one or more accessory ingredients.
• active ingredient a compound
• the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired composition.
• compositions suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets (e.g. chewable tablets in particular for paediatric administration) each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in- water liquid emulsion or a water-in-oil liquid emulsion.
• the active ingredient may also be presented as a bolus, electuary or paste.
• a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
• Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a other conventional excipients such as binding agents, (for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone), fillers (for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol), lubricants (for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica), disintegrants (for example, potato starch or sodium starch glycollate) or wetting agents, such as sodium lauryl sulfate.
• binding agents for example, syrup, acacia, gelatin, sorbitol, tragacanth, m
• Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
• the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
• the tablets may be coated according to methods well-known in the art.
• a compound of the present invention may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, for example.
• compositions containing these compounds may be presented as a dry product for constitution with water or other suitable vehicle before use.
• Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible fats; emulsifying agents such as lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives such as methyl or propyl p-hydroxybenzoates or sorbic acid.
• Such preparations may also be formulated as suppositories, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
• compositions for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
• compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of a sterile liquid carrier, for example, water-for-injection, immediately prior to use.
• a sterile liquid carrier for example, water-for-injection
• Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
• compositions for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter, hard fat or polyethylene glycol.
• compositions for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
• the compounds may also be formulated as depot preparations. Such long acting compositions may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
• the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• compositions may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
• treatment extends to prophylaxis as well as the treatment of established diseases or symptoms.
• amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian.
• doses employed for adult human treatment will typically be in the range of 0.02-5000 mg per day, preferably 1-1500 mg per day.
• the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
• the formulations according to the invention may contain between 0.1-99% of the active ingredient, conveniently from 30-95% for tablets and capsules and 3-50% for liquid preparations.
• a compound of the invention may be used in combination with other therapeutic agents for example, statins (HMG Co A reductase inhibitors) and/or other lipid lowering drugs for example MTP inhibitors and LDLR upregulators.
• statins HMG Co A reductase inhibitors
• other lipid lowering drugs for example MTP inhibitors and LDLR upregulators.
• the compounds of the invention may also be used in combination with antidiabetic agents, e.g. metformin, sulfonylureas and/or PPAR gamma agonists (for example thiazolidinediones such as e.g. Pioglitazone and Rosiglitazone).
• PPAR gamma agonists for example thiazolidinediones such as e.g. Pioglitazone and Rosiglitazone.
• antihypertensive agents such as calcium channel antagonists and ACE inhibitors.
• the invention thus provides in
• the compounds may be administered either sequentially or simultaneously by any convenient route.
• compositions comprising a combination as defined above optimally together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention.
• the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical compositions.
• the two compounds When combined in the same composition it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the composition and may be formulated for administration. When formulated separately they may be provided in any convenient composition, conveniently in such a manner as are known for such compounds in the art.
• each compound of formula (I) When a compound of formula (I) is used in combination with a second therapeutic agent active against the same hPPAR mediated disease, the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
• R in formula (C) is preferably C ⁇ -6 alkyl. Note this synthesis is preferably carried out with the acid group of moiety A protected by R.
• R can be H, preferably R is C 1-6 alkyl which can be hydrolyzed off to give an acid of Formula (I), or if readily hydrolyzable, the resulting ester can be administered.
• Scheme 3 is advantageous over Schemes 1 and 2 in that there is provided a method of achieving regio selectivity for the substituted pyrazole group as compared to Schemes 1 and 2 above which have to be resolved by chromatography.
• g (grams); mg (milligrams); L (liters); mL (milliliters); ⁇ L (microliters); mM (millimolar); mol (moles); mmol (millimoles); rt (room temperature); min (minutes); h (hours); MeOH (methanol); EtOH (ethanol); THF (tetrahydrofuran); AcOEt (ethyl acetate); Ac (acetyl); HOBT (1-Hydroxybenzotriazole); DMF (N,N-,dimethyl formamide); HOAT (1-Hydroxy-7- azabenzotriazole); HOBT (1-Hydroxybenzotriazole); EDCI (1-(3-Dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride)); HATU 0-(7-Azabenzotriazol-1-yl)-N,N,N',N'- te
• Example 3 (90mg, 0.18 mmol), ammonium formate (120 mg, 1.9 mmol) and Pd/C10% (50mg) were stirred in 50 mL of ethanol for 2 hours at rt, then for 18 hours at 60°C. The reaction mixture was filtered through a celite pad and the resulting product was purified by preparative HPLC to afford the title compound as a pale pink powder (20mg).
• Example 6 2-f ⁇ 4- f(f 5-
• Example 7 2-methyl-2-r(2-methyl-4-fr(f1-methyl-5-r4-(2-methylpropyl) phenylM H-pyrazol-3-yll carbonyl) aminol methyl ⁇ phenyl) oxylpropanoic acid.
• Example 8 2-methyl-2-r(2-methyl-4-fr((1-methyl-3-r4-(2-methylpropyl) phenylM H-pyrazol-5-yl) carbonyl) aminol methyl) phenyl) oxylpropanoic acid.
• Intermediate 35 (202 mg, 0.41 mmol) was dissolved in 2 mL of THF and 15 mL of ethanol and 4.1 mL (4.1 mmol) of 1 N NaOH were added. The solution was heated to 80°C for 2.5 hours and concentrated under vacuum. The residue was diluted in 10 mL of water and acidified with 1 N HCI and the white solid was filtered off and dried under reduced pressure at 50°C to provide the title carboxylic acid as 185 mg of a white powder. Yield : 97%
• intermediate 48 To a hot (70°C) solution of intermediate 48 (31.4 g, 0.105 mol) in 500 mL of ethanol was added two volumes of methylhydrazine (5.85 mL, 0.11 mol), then it was stirred at 90°C for 2h. The resulting mixture was concentrated to dryness, dissolved in ethylacetate, washed with HCI (1 N), brine, dried on Na 2 SO and evaporated to dryness, then purified by flash chromatography (Cyclohexane/ethylacetate 90/10 to 70/30) to obtain two products, intermediate 49 first eluted and intermediate 50 :
• reaction mixture was stirred under nitrogen at 100°C for 16h, then filtered through celite with CH 2 CI 2 , evaporated to dryness and purified by flash chromatography (CH 2 CI 2 /Ethylacetate 95/5) to give the product (163mg).
• intermediate 10 (2.24 g, 7.8mmol) with 3.27 mL (23.4mmol) of Et 3 N in 150 mL of CH 2 CI 2 anhydrous was added intermediate C (diluted in 100 mL of CH 2 CI 2 ), then it was stirred at rt for 16h. The resulting mixture was treated with 150 mL of HCI (1 N), the organic layer was extracted and washed with 150 mL of NaOH (1 N), brine, dried on Na 2 SO 4 and under vacuum to give an amorphous solid (3.5g).
• intermediate D To a solution of intermediate 63 (2.2g, 7.8 mmol) in 100 mL of toluene was added 2.86 mL (40mmol) of SOCI 2 , and was stirred at 110°C for 3h. Then the reaction mixture was evaporated twice with toluene to eliminate the excess of SOCI 2 to give the intermediate D. To a solution of intermediate 153 (2.25 g, 7.8mmol) and 3.3 mL ( 23.5mmol) of Et 3 N in 100 mL of CH 2 CI 2 anhydrous was added dropwise, intermediate D diluted in 50 mL of CH 2 CI 2 .
• Ethyl 5-f4-(1.1 -dimethylethyl)phenyll-2.4-dioxopentanoate At 0°C, 320 mg (13.9mmol) of sodium was added to 30 mL of ethanol and it was stirred until complete solubility of Na. At 0°C, 2.4g (12.6mmol) of intermediate 103 in 5 mL of ethanol was added via a syringe and the solution was stirred for 1h. At 0°C, 1.89 mL (13.9mmol) of ethyl oxalate in 5 mL of methanol were added.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Child & Adolescent Psychology (AREA)
• Hospice & Palliative Care (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Nutrition Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (4)

Publications (1)

Family

ID=34621661

Family Applications (1)

Country Status (9)

Cited By (24)

Families Citing this family (8)

Citations (3)

Family Cites Families (4)

• 2004
  • 2004-11-12 TW TW093134800A patent/TW200526588A/zh unknown
  • 2004-11-15 WO PCT/EP2004/012965 patent/WO2005049578A1/en not_active Ceased
  • 2004-11-15 DE DE602004015498T patent/DE602004015498D1/de not_active Expired - Fee Related
  • 2004-11-15 JP JP2006538823A patent/JP2007511485A/ja active Pending
  • 2004-11-15 AT AT04818779T patent/ATE402926T1/de not_active IP Right Cessation
  • 2004-11-15 US US10/595,868 patent/US20080021030A1/en not_active Abandoned
  • 2004-11-15 ES ES04818779T patent/ES2311179T3/es not_active Expired - Lifetime
  • 2004-11-15 EP EP04818779A patent/EP1685113B1/en not_active Expired - Lifetime
  • 2004-11-15 AR ARP040104209A patent/AR046625A1/es unknown

Patent Citations (3)

Also Published As

Similar Documents

Legal Events